Liminatus Pharma (LIMN) Total Non-Current Liabilities (2025 - 2026)

Liminatus Pharma (LIMN) posted Total Non-Current Liabilities of $2.9 million for Q1 2026, down 71.94% sequentially from $10.3 million in Q4 2025.

Liminatus Pharma (LIMN) Total Non-Current Liabilities (2025 - 2026) Analysis & Trends

Liminatus Pharma has reported Total Non-Current Liabilities for 2 years, with the latest figure at $2.9 million in Q1 2026.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (changed N/A YoY) and the FY2025 annual result came in at $10.3 million, changed N/A from the prior year.
Total Non-Current Liabilities retreated to $2.9 million in Q1 2026 per LIMN's latest filing, from $10.3 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $10.5 million in Q2 2025 and troughed at $2.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	40.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.20 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.17 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.32 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	724.15 Mn
10	Liminatus Pharma	5.46 Mn	5.46 Mn	-	3.04 Mn

Download Data